DRTS News & Events

Alpha Tau announced the treatment of the first patient in ACAPELLA, the company's European multicenter clinical trial evaluating Alpha DaRT combined with capecitabine for patients with inoperable locally advanced pancreatic ductal adenocarcinoma who have completed first-line mFOLFIRINOX chemotherapy. The procedure was performed at CHU Grenoble Alpes by Pr. Gael Roth, Lead Investigator of ACAPELLA, and his team, marking the first use of Alpha DaRT for pancreatic cancer in Europe.

Alpha Tau announced that the FDA has approved an investigational device exemption supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT, evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. The IDE supplement expands the trial to allow ten additional newly diagnosed patients receiving gemcitabine/nab-paclitaxel together with Alpha DaRT, five of whom with unresectable locally advanced pancreatic cancer and five with metastatic pancreatic cancer. Together with the previous IDE approval to recruit 30 patients in this trial for treatment with Alpha DaRT together with mFOLFIRINOX, the IMPACT trial is now expected to recruit a total of 40 patients.